Side effects of high-dose interferon therapy for chronic hepatitis C

Journal of Hepatology

Volumn 25, Issue 3, 1996, Pages 283-291

  Okanoue, Takeshi ^a   Sakamoto, Shinichi ^a   Itoh, Yoshito ^a   Minami, Masahito ^a   Yasui, Koichiro ^a   Sakamoto, Masafumi ^a   Nishioji, Kenichi ^a   Katagishi, Tatsuo ^a   Nakagawa, Yoshihiro ^b   Tada, Hisashi ^b   Sawa, Yoshihiko ^c   Mizuno, Masayuki ^d   Kagawa, Keizo ^a   Kashima, Kei ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Department of Radiology   (Japan)

^c Aiseikai Yamashima Hospital   (Japan)

^d YODOGAWA CHRISTIAN HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Hearing impairment; Ischemic colitis; Retinal detachment; Side effects of alpha interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTINUCLEAR ANTIBODY; DNA ANTIBODY; LYMPHOBLAST INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; THYROTROPIN;

ADULT; AGED; ALOPECIA; AMNESIA; ARTICLE; AUTOIMMUNITY; CHRONIC HEPATITIS; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DIAGNOSIS; DUODENUM BLEEDING; EPIDEMIOLOGY; FEMALE; HEARING LOSS; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFLUENZA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; RETINOPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

EID: 0030248901     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80113-9     Document Type: Article

References (43)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Tamburro C, Lefkowitch J, Albrecht J, Mesievitz C, Ortego TJ, Gibas A. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. New Engl J Med. 321:1989;1501-1506.
2. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. A randomized, double-blind, placebo-controlled trial. New Engl J Med. 321:1989;1506-1510.
3. Marcellin P, Boyer N, Giotra E, Degotte C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou J.-P. Recombinant human α-interferon in patients with non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
4. Burman P, Totterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long-term therapy with leukocyte-derived interferon. J Clin Endocrinol Metabol. 63:1986;1086-1090.
5. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones B, Rustgi V, Jones A. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med. 147:1987;1577-1580.
6. Hoofnagle JH, Peters MG, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Jones EA. Randomized controlled trial of a four-month course of recombinant human alfa interferon in chronic type B hepatitis. Gastroenterology. 95:1988;1318-1325.
7. Mayet W-J, Hess G, Gerken G, Rossol S, Voth R, Manns M, Meyer Zum Buschenfelde K.-H. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology. 10:1989;24-28.
8. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis. 9:1989;273-277.
9. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraubs B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology. 102:1992;2155-2160.
10. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Safety. 10:1994;115-150.
11. Mizoguchi Y. Diagnosis of drug-induced hepatitis. Mizoguchi Y. Disease of Drug-Induced Hepatitis. 1989;51-74 Shinko-Igaku Schutsupan, Tokyo.
12. Ronnblom LE, Alm GV, Oberz KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumor. Ann Intern Med. 115:1991;178-183.
13. Chung YH, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-α 2b for chronic viral hepatitis. Am J Gastroenterol. 88:1993;244-247.
14. Pateron D, Hartmann DJ, Duclos Vallee JC, Jouanolle H, Beaugrand H. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol. 16:1992;244-245.
15. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier P, Sadoul J-L, Hebuterne X, Rampal P. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 18:1993;253-257.
16. Marcellin P, Pouteau M, Benhamou J.-P. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. Review J Hepatol. 22:1995;364-369.
17. Schultz M, Muller R, Von zur Muhlen A, Braband G. Induction of hyperthyroidism by interferon-α-2b. (letter) Lancet. i:1989;1453.
18. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W, Weissel M. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol. 90:1992;363-367.
19. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes. 38:1989;641-649.
20. Fabris P, Beterlle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, Charamonte M. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. (letter) Lancet. 340:1992;548.
21. Kamitsukasa H, Ohtake M, Kawashima H, Yagura M, Harada H, Katayama T. Two cases of interstitial pneumonia induced by interferon therapy for chronic aggressive hepatitis type C. Acta Hepatol Jpn. 39:1993;478-483.
22. Tsukiyama K, Tasaka Y, Nakajima M, Hino J, Nakahara C, Okimoto N, Yagi S, Soejima R. A case of pneumonitis due to Sho-Sai-Koto. Jpn J Thorac Dis. 27:1989;1556-1561.
23. Schattner A. Interferons and autoimmunity. Am J Med Sci. 295:1988;532-544.
24. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer. 65:1990;2237-2242.
25. Silva MO, Reddy R, Jeffers LJ, Hill M, Schiff ER. Interferon-induced chronic active hepatitis. Gastroenterology. 101:1991;840-842.
26. Papo T, Marcellin P, Bernauau J, Durand F, Poynard T, Benhamou J.-P. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med. 116:1992;51-53.
27. Itoh Y, Okanoue T, Enjyo F, Morimoto M, Takeuchi T, Kagawa K, Kashima K. Elevated interleukin-6 and γ-globulin during interferon therapy of chronic hepatitis B. Am J Gastroenterol. 87:1992;1485-1487.
28. Mehta ND, Hooberman AL, Vokes EE, Neeley S, Cotler S. 35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after alpha-interferon therapy. Am J Hematol. 41:1992;141.
29. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer. 68:1991;1536-1537.
30. Nadir F, Fagiuoli S, Wright HI, Nadir A, Hopp E, Gavaler J, Van Thiel DH. Rheumatoid arthritis: a complication of interferon therapy. J Okla State Med Assoc. 87:1994;228-230.
31. McLaughlin P, Talpaz M, Quesada JR, Saleem A, Barlogie B. Immune thrombocytopenia following alpha-interferon therapy in patients with cancer. J Am Med Assoc. 253:1985;1353-1354.
32. Lopez Morante AJ, Saez-Royuela F, Casanova Valero F, Yequero del Moral L, Martin Lorente JL, Gimenez CO. Immune thrombocytopenia after alpha-interferon therapy in a patient with chronic hepatitis C. Am J Gastroenterol. 87:1992;809-810.
33. Akard LP, Hoffman R, Elias L, Saiers JH. Alpha-interferon and immune hemolytic anemia. Ann Intern Med. 105:1986;306.
34. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 4:1986;234-243.
35. Pecorai P. Colite ulcerosa in corso di leucemia a cellule capellute. Descrizione di un caso. Rec Prog Med. 82:1991;269-271.
36. Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley S, Gucalp R, Ciobanu N, Grirna K, Wiernik PH, Brandt LJ. Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. Cancer. 68:1991;1538-1544.
37. Guyer DR, Tiederman J, Yannuzzi LA, Slakter JS, Parke D, Kelley J, Tang RA, Marmor M, Abrams G, Miller JW, Gragoudas ES. Interferon-associated retinopathy. Arch Ophthalmol. 111:1993;350-356.
38. Seki K, Itoh Y, Nishi Y, Isaka Y. Interferon therapy for type C chronic active hepatitis and retinal hemorrhage. Acta Hepatol Jpn. 17:1993;385-391.
39. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, Rustgi V, Jones EA. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med. 147:1989;1577-1580.
40. Prasad S, Waters B, Hill PB, Portera FD, Riely CA. Psychiatric side effects of interferon alpha2b in patients treated for hepatitis C. Abstract Clin Res. 40:1992;840A.
41. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioural changes in patients with renal cell carcinoma. Eur J Cancer. 26:1990;595-600.
42. Kanda Y, Shigeo K, Kinoshita N, Nakano K, Yano M, Matsuo H. Sudden hearing loss associated with interferon. Lancet. 343:1994;1134-1135.
43. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y, Shimizu Y, Inoue A, Fusamato H, Kamada T. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology. 21:1995;291-297.